Melany Durand

Bordeaux, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteers.

CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteers.

Journal: Scientific reports

Published: January 06, 2026

Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06).

Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06).

Journal: EClinicalMedicine

Published: July 08, 2024

Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial.

Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial.

Journal: The Journal of infectious diseases

Published: March 15, 2024

Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo.

Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo.

Journal: Cell reports

Published: April 11, 2023

Erratum: CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.

Erratum: CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.

Journal: iScience

Published: January 02, 2023

T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial.

T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: November 17, 2021

CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.

CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.

Journal: iScience

Published: February 08, 2021

Long-lasting severe immune dysfunction in Ebola virus disease survivors.

Long-lasting severe immune dysfunction in Ebola virus disease survivors.

Journal: Nature communications

Published: September 05, 2019

Showing 1-8 of 8

Last Updated: 09/26/2026